Market Report on Plasminogen Activator Inhibitor-1- Pipeline Review, H1 2016

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted pipeline therapeutics.

The report provides comprehensive information on the Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit ​Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1)
- The report reviews Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report assesses Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Companies Mentioned

D-Pharm Ltd. Jazz Pharmaceuticals Plc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###